MGC018 With or Without MGA012 in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Castrate Resistant Prostate Cancer
Melanoma
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Advanced Solid Tumor, Adult

Interventions: Biological: vobramitamab duocarmazine

Registration Number: NCT03729596

Lead Sponsor: MacroGenics

Brief Summary: The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 143

Inclusion Criteria

Tissue specimen available for retrospective analysis of B7-H3 and PD-L1 expression.
Eastern Cooperative Oncology Group performance status of ≤2
Life expectancy ≥ 12 weeks for dose escalation phase and ≥ 24 weeks for cohort expansion phase
Measurable disease. Prostate cancer patients with bone only disease are eligible.
Acceptable laboratory parameters and adequate organ reserve.
Dose Escalation Phase: Patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no therapy with demonstrated clinical benefit is available.

Module A Cohort Expansion:

mCRPC that has progressed with one prior line of chemotherapy for metastatic disease and no more than two prior lines of anti-hormonal therapy.
NSCLC: metastatic disease after standard cytotoxic, targeted, and biologic or checkpoint inhibitor therapy. No more than 2 prior lines of chemotherapy.
TNBC: Locally advance or metastatic disease that has progressed following at least one systemic therapy.
SCCHN that has progressed during or following at least one systemic therapy for metastatic or recurrent unresectable disease. No more than 2 prior lines of chemotherapy.
Melanoma that has progressed during or following at least one systemic treatment for unresectable locally advanced or metastatic disease. Patients who are intolerant of or refused standard therapy are eligible.

Exclusion Criteria

Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on MRI, CT or PET within 6 months, or history of leptomeningeal disease or cord compression at the time of enrollment.
Prior treatment with B7-H3 targeted agents for cancer.
Treatment with systemic cancer therapy, biologic agents, or anti-hormonal therapy (mCRPC) within 4 weeks, prior small molecule targeted or kinase inhibitors within 14 days or 5 half-lives, prior radioligand within 6 months
Clinically significant cardiovascular disease.
Clinically significant pulmonary compromise or requirement for supplemental oxygen.
History of clinically-significant cardiovascular disease, including but not limited to pericarditis or pericardial effusion.
Active viral (including confirmed or presumed COVID-19), bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration.
Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.
Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
Major trauma or major surgery within 4 weeks of first study drug administration.
Clinically significant venous insufficiency.
> Grade 1 peripheral neuropathy.
Evidence of pleural effusion.
Evidence of ascites.
Serum testosterone >50 ng/dl or >1.7 nmol/L in mCRPC in Module A Cohort Expansion Phase

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 1	vobramitamab duocarmazine	0.5 mg/kg IV every 3 weeks
Cohort 2	vobramitamab duocarmazine	1.0 mg/kg IV every 3 weeks
Cohort 3	vobramitamab duocarmazine	2.0 mg/kg IV every 3 weeks
Cohort 4	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks
Cohort 5	vobramitamab duocarmazine	4.0 mg/kg IV every 3 weeks
mCRPC expansion	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks
NSCLC expansion	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks
SCCHN expansion	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks
TNBC expansion	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks
Melanoma expansion	vobramitamab duocarmazine	3.0 mg/kg IV every 3 weeks

Primary Outcome Measures

Name	Time	Method
Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03	Throughout the study up to 24 months	Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.
Number of Participants With Dose Limiting Toxicities (DLT)	up to 42 days from first dose	Number of participants with severe side effects from study treatment during the DLT evaluation period (6 weels)

Secondary Outcome Measures

Name	Time	Method
Best Overall Response (BOR) of Vobramitamab Duocarmazine	Throughout the study for up to 24 months	The best response recorded from the start of the study treatment until the end of treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, taking into account any requirement for confirmation of response. Complete response (CR) is defined as disappearance of all target and non-target lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions, and no new lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of non-target lesions, or appearance of new lesions. Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progression. Not evaluable (NE) is where the response cannot be determined.
Objective Response Rate (ORR) of Vobramitamab Duocarmazine	Efficacy evaluations every 9 weeks throughout the study for up to 24 months	The percentage of participants who achieve a complete response (CR or partial response (PR) to treatment with vobramitamab duocarmazine
Progression Free Survival (PFS) of Vobramitamab Duocarmazine	Every 9 weeks for up to 24 months	PFS is calculated from the first dose date until the date of first documented PD using RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of non-target lesions, or appearance of new lesions. Median PFS and 95% CI is estimated using the Kaplan-Meier method.
Median Duration of Response (DoR) of Vobramitamab Duocarmazine	Throughout the study for up to 48 months	Median DoR assessed as the time from the date of initial objective response to the date of first documented PD, per RECIST v1.1, or the date of death from any cause, whichever occurs first. Median DoR and 95% CI is estimated using the Kaplan-Meier method.
Median Overall Survival (OS) of Vobramitamab Duocarmazine	Every 9 weeks for up to 24 months	Median OS assessed as the time from the first dose date to the date of death from any cause, using the Kaplan-Meier method for estimating median and confidence interval. .
PSA Response Rate	Every 3 weeks up to 24 months	Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA) with confirmation at least 3 weeks later
Best PSA Response	Every 3 weeks up to 24 months	For prostate cancer patients, the greatest change from baseline in PSA.
Mean Area Under the Curve (AUC) of Vobramitamab Duocarmazine Antibody Drug Conjugate (ADC)	At baseline, Cycle 1, Day 1: 1 hour, 4 hours after the first dose, Day 2, Day 3, Day 7, Day 14 and Cycle 2 Day 1 (approximately 21 days after the first dose).	Area under the plasma concentration versus time curve of vobramitamab duocarmazine
Mean AUC of Duocarmycin	At baseline, Cycle 1, Day 1: 1 hour, 4 hours after the first dose, Day 2, Day 3, Day 7, Day 14 and Cycle 2 Day 1 (approximately 21 days after the first dose).	Area under the plasma concentration versus time curve of duocarmycin (unconjugated payload) in the bloodstream
Mean Maximum Concentration Vobramitamab Duocarmazine ADC	At baseline, Cycle 1, Day 1, 1 and 4 hours after the end of infusion, Day 2, and Day 3.	Maximum Plasma Concentration of vobramitamab duocarmazine ADC in the bloodstream
Mean Maximum Concentration Duocarmycin	At baseline, Cycle 1, Day 1, 1 and 4 hours after the end of infusion, Day 2, and Day 3.	Maximum Plasma Concentration of vobramitamab duocarmazine ADC in the bloodstream
Mean Trough Concentration of Vobramitamab Duocarmazine ADC	At baseline, and before subsequent infusion Cycle 2, Day 1 (Study Day 22).	Average trough plasma concentration of vobramitamab duocarmazine ADC in the bloodstream.
Mean Trough Concentration of Duocarmycin	At baseline, and before subsequent infusion Cycle 2, Day 1 (Study Day 22).	Average trough plasma concentration of duocarmycin unconjugated payload in the bloodstream.
Number of Participants Who Develop MGC018 Anti-drug Antibodies	Every 3 weeks through end of treatment, up to 24 months	Shifts in MGC018 anti-drug antibodies after treatment with vobramitamab duocarmazine

Trial Locations

Locations (21): UCLA Department of Medicine - Hematology/Oncology
🇺🇸
Santa Monica, California, United States
Sibley Memorial Hospital
🇺🇸
Washington, District of Columbia, United States
The Johns Hopkins Kimmel Cancer Center
🇺🇸
Baltimore, Maryland, United States
START Midwest
🇺🇸
Grand Rapids, Michigan, United States
Nebraska Methodist Hospital
🇺🇸
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
🇺🇸
Las Vegas, Nevada, United States
Carolina Biooncology Institute
🇺🇸
Huntersville, North Carolina, United States
Inova Schar Cancer Institute
🇺🇸
Fairfax, Virginia, United States
Virginia Cancer Specialist
🇺🇸
Fairfax, Virginia, United States
St Vincent's Health Network (Kinghorn Cancer Centre)
🇦🇺
Darlinghurst, Australia
Scroll for more (11 remaining)
UCLA Department of Medicine - Hematology/Oncology
🇺🇸Santa Monica, California, United States